Back to Search
JULIO ROSENSTOCK, M.D.
M.D.
Endocrinology, Diabetes & Metabolism Physician
NPI: 1831133529Individual
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
G9206(TX)
Research & Publications (20)
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
PMID 19526210·Diabetologia·2009
4-observational
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
PMID 19383032·Diabetes Obes Metab·2009
4-observational
Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
PMID 19592625·Diabetes Care·2009
2-rct
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
PMID 19650754·Curr Med Res Opin·2009
2-rct
Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes.
PMID 18535196·Diabetes Care·2008
2-rct
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
PMID 18355324·Diabetes Obes Metab·2008
4-observational
Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.
PMID 18269437·Int J Clin Pract Suppl·2008
6-review
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
PMID 18204830·Diabetologia·2008
4-observational
Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
PMID 18201206·Diabetes Obes Metab·2008
2-rct
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
PMID 17947341·Diabetes Care·2008
4-observational
Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy.
PMID 17934150·Diabetes Care·2008
2-rct
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.
PMID 18678611·Diabetes Care·2008
2-rct
Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.
PMID 18678610·Diabetes Care·2008
4-observational
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
PMID 17300593·Diabetes Obes Metab·2007
4-observational
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
PMID 17940427·Curr Opin Endocrinol Diabetes Obes·2007
6-review
Reflecting on type 2 diabetes prevention: more questions than answers!
PMID 17877541·Diabetes Obes Metab·2007
6-review
AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes.
PMID 17850203·Expert Rev Med Devices·2007
6-review
A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
PMID 17363756·Diabetes Care·2007
4-observational
Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures.
PMID 17316102·Diabetes Technol Ther·2007
3-trial
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
PMID 17259484·Diabetes Care·2007
2-rct
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7777 FOREST LN, SUITE C-685
DALLAS, TX 75230 - Phone
- (972) 566-7799
Quick Facts
- NPI
- 1831133529
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile